

MSIL: CSL: NSE&BSE: 2018

27th July, 2018

Vice President
National Stock Exchange of India Limited
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051

General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Subject: Copy of published unaudited results

Dear Sir,

Please find attached herewith the copy of unaudited financial results for the quarter ended 30th June, 2018 as published in requisite newspaper as per the requirement of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on record.

Thanking you,

Yours truly,

For Maruti Suzuki India Limited



Sanjeev Grover
Chief General Manager
& Company Secretary

Enc.: As above

MARUTI SUZUKI INDIA LIMITED

CIN: L34103DL1981PLC011375

Registered & Head Office
Maruti Suzuki India Limited,
1 Nelson Mandela Road, Vasant Kunj,
New Delhi 110070, India.
Tel: 011-46781000, Fax: 011-46150275/46150276
www.marutisuzuki.com

Gurgaon Plant:
Maruti Suzuki India Limited,
Old Palam Gurgaon Road,
Gurgaon 122015, Haryana, India.
Tel. 0124-2346721, Fax: 0124-2341304

Manesar Plant:
Maruti Suzuki India Limited,
Plot No.1, Phase 3A, IMT Manesar,
Gurgaon 122051, Haryana, India.
Tel: 0124-4884000, Fax: 0124-4884199

Biocon profit jumps 47% in June quarter

AGENCIES
Bengaluru/New Delhi, July 26

BIOCON REPORTED A 47% rise in the June quarter profit on Thursday, helped by higher income from its biologics and research services businesses.

Net profit rose to ₹120 crore for the quarter ended June 30, from ₹81.3 crore last year, India's largest biotechnology company, said in a statement. Revenue from operations rose 20.4% to ₹1,124 crore. Analysts on average were expecting a net profit of ₹117 crore, according to Thomson Reuters.

"We started the year with a robust Q1FY19 recording an overall revenue growth of 21% at ₹1,193 crore and a 47% rise in net profit at ₹120 crore, driven by a strong performance across our business segments," Biocon chairperson and MD Kiran Mazumdar-Shaw said.

Dr Reddy's posts eight-fold jump in net

FE BUREAU
Hyderabad, July 26

DR REDDY'S LABORATORIES has posted an eight-fold jump in its consolidated net profit, clocking ₹456.1 crore against ₹59.1 crore, aided by operational efficiencies, forex gains and launch of gSuboxone, the generic version of an opioid addiction drug in the US market during the first quarter.

Consolidated revenues stood at ₹3,720.7 crore against ₹3,315.9 crore in the same quarter last year. Earnings before interest, tax, depreciation and amortisation (Ebitda) for the quarter stood at ₹807.1 crore, an increase of 140% year-on-year (y-o-y).

"Our focus on operational efficiencies has helped in significantly improving our margin profile. Looking ahead, while we may continue to experience price erosion in the North America Generics

market, we will also continue to drive growth and cost efficiencies, at the same time, enhancing our quality management systems and building healthy portfolios across the markets we serve," company co-chairman and CEO, GV Prasad said.

The focus will continue on building complex generics, biosimilars and differentiated products pipeline, he added.

"Part of the gross margin improvement is attributed to gSuboxone, but there has been benefit from forex gains and operating efficiencies as well.



The forex gain has also contributed 400-500 basis points to the profit," Saumen Chakraborty, President, CFO and global head of HR, Dr Reddy's, said.

The company was selling

Consolidated revenues stood at ₹3,720.7 crore against ₹3,315.9 crore in the same quarter last year, while Ebitda stood at ₹807 crore, an increase of 140%

generic product in the US market prior to the grant of a temporary restraining order (TRO). To recall, the New Jersey District Court has granted a preliminary injunction against Dr Reddy's on the sale of a generic

version of Indivior's prescription medicine gSuboxone in the US market. The court has prevented Dr Reddy's from re-launching its generic product until the patent litigation by Indivior is concluded or until it prevails on an appeal of this injunction.

Revenues from emerging markets, which contribute 18% of generic sales business, declined 21% to ₹664.3 crore. However, revenues from Russia grew 9% to ₹380 crore on account of new launches and volume traction in some of the key molecules.

Colgate-Palmolive Q1 net profit at ₹190 cr

New Delhi, July 26

FMCG MAJOR Colgate-Palmolive India (CPIL) on Thursday reported net profit of ₹189.51 crore for the first quarter of 2018-19, led by strong volume growth.

The company had posted net profit of ₹136.38 crore in the April-June quarter last fiscal, 2017-18, CPIL said in a BSE filing.

Net sales during the quarter under review were at ₹1,033.55 crore. They were at ₹1,109.88 crore in the year-

ago period.

CPIL MD Issam Bachalrani said: "The company registered volume growth of 4% in the first quarter with strong performance in naturals portfolio."

According to the company, the sales for the quarter are net of GST, while the year-ago figures include excise duty which has now been subsumed after implementation of GST. Hence, the results are not comparable.

Its total expenses were also down 14.40% to ₹799.10 crore.

MARUTI SUZUKI
Way of Life!

MARUTI SUZUKI INDIA LIMITED

Registered Office: Plot No.1, Nelson Mandela Road, Vasant Kunj, New Delhi - 110070

CIN: L34103DL1981PLC011375; Website: www.marutisuzuki.com; E-mail: investor@maruti.co.in; Phone: +91-11-46781000; Fax: +91-11-46150275/76

INR in million, except per share data

Sl. No.	Particulars	Quarter ended			Year ended
		30th June, 2018	31st March, 2018	30th June, 2017	31st March, 2018
		Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations	224,594	211,656	197,774	819,944
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	28,824	26,344	22,987	110,034
3	Net Profit / (Loss) for the period (before Tax, after Exceptional and / or Extraordinary Items)	28,824	26,344	22,987	110,034
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	19,753	18,821	15,564	77,218
5	Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	19,606	17,710	16,281	80,530
6	Equity Share Capital	1,510	1,510	1,510	1,510
7	Earnings Per Share (of INR 5 each) (for continuing and discontinued operations)				
	(a) Basic	65.39	62.30	51.52	255.62
	(b) Diluted	65.39	62.30	51.52	255.62

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com and on Company's website at www.marutisuzuki.com.

For and on behalf of Board of Directors

New Delhi
26th July, 2018

(Kenichi Ayukawa)
Managing Director & CEO

A. K. CAPITAL SERVICES LTD.
BUILDING BONDS
Regd. Office: 403, 4th Floor, East Wing, Tulsiani Chambers, Free Press Journal Marg, 212, Nariman Point, Mumbai - 400021.
CIN: L74899MH1993PLC274881 | Website: www.akgroup.co.in
Tel: +91-22-67546500 | Fax: +91-22-66100594 | E-mail: compliance@akgroup.co.in

NOTICE OF RECORD AND BOOK CLOSURE DATE
In pursuance to the Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at their Meeting held on Saturday, May 26, 2018 had decided Friday, August 10, 2018 as the "Record Date" for the purpose of ascertaining the eligibility of the shareholders for the payment of final dividend if approved at the ensuing Annual General Meeting.

Further, pursuant to Section 91 of the Companies Act, 2013 and Rule 10 of the Companies (Management and Administration) Rules, 2014 read with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and the Share Transfer Books of the Company will remain closed from Saturday, August 11, 2018 to Saturday, August 18, 2018 (both days inclusive) in order to ascertain the entitlement of final dividend, if declared at the ensuing Annual General Meeting.

The said notice is also available on www.bseindia.com and www.akgroup.co.in.

For A. K. Capital Services Limited
Sd/-
A. K. Mittal
Managing Director
(DIN: 00698377)

Date: July 26, 2018
Place: Mumbai

SUN PHARMA
REGD. OFFICE: SPARC, Tandajda, Vadodara - 390 012
CORPORATE OFFICE: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon-East, Mumbai - 400 063
CIN: L24230GJ1993PLC019050 | Website: www.sunpharma.com
Tel: 022-43244324/022-43241234

NOTICE
NOTICE is hereby given pursuant to Regulation 47(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the Meeting of the Board of Directors of the Company will be held on Tuesday, August 14, 2018, inter alia, to consider and take on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2018.

This Notice is also available on the Company's website www.sunpharma.com and on the websites of BSE Limited and National Stock Exchange of India Limited i.e. www.bseindia.com and www.nseindia.com respectively.

By order of the Board of Directors
For Sun Pharmaceutical Industries Limited
Sd/-
Ashok I. Bhuta

Place: Mumbai
Date: July 26, 2018
Sr. GM - Secretarial & Compliance Officer

YES BANK

SUSTAINED FINANCIAL PERFORMANCE



* including profits & adjusted for prorated dividend & IFR

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

PARTICULARS (₹ in Crores)	FOR THE QUARTER ENDED 30.06.18 (Unaudited)	FOR THE QUARTER ENDED 31.03.18 (Audited Ref Note 11)	FOR THE QUARTER ENDED 30.06.17 (Unaudited)	FOR THE YEAR ENDED 31.03.18 (Audited)
1 Interest earned (a)+(b)+(c)+(d)	6,578.04	5,742.98	4,653.80	20,267.42
(a) Interest/discount on advances/bills	5,004.66	4,404.41	3,534.48	15,478.24
(b) Income on investments	1,350.86	1,179.44	902.72	4,102.53
(c) Interest on balances with Reserve Bank of India and other inter-bank funds	162.03	109.60	179.36	516.07
(d) Others	60.49	49.53	37.24	170.58
2 Other Income (Refer Note 4)	1,694.14	1,420.97	1,132.16	5,223.83
3 TOTAL INCOME (1+2)	8,272.18	7,163.95	5,785.96	25,491.25
4 Interest Expended	4,358.90	3,588.74	2,844.87	12,530.36
5 Operating Expenses (i)+(ii)	1,458.57	1,439.78	1,236.89	5,212.78
(i) Payments to and provisions for employees	590.62	546.67	546.11	2,188.92
(ii) Other operating expenses	867.95	893.11	690.78	3,023.86
6 Total Expenditure (4+5) (excluding provisions & contingencies)	5,817.47	5,028.52	4,081.76	17,743.14
7 Operating Profit (before Provisions and Contingencies)(3-6)	2,454.71	2,135.43	1,704.20	7,748.11
8 Provisions (other than Tax expense) and Contingencies (net)	625.65	399.64	285.78	1,553.80
9 Exceptional Items	-	-	-	-
10 Profit from ordinary activities before tax (7-8-9)	1,829.06	1,735.79	1,418.42	6,194.31
11 Tax Expense	568.70	556.35	452.90	1,969.75
12 Net profit from Ordinary Activities after tax (10-11)	1,260.36	1,179.44	965.52	4,224.56
13 Extraordinary Items (Net of tax)	-	-	-	-
14 NET PROFIT (12-13)	1,260.36	1,179.44	965.52	4,224.56
15 Paid-up equity Share Capital (Face value of ₹ 2 each)	461.14	460.59	457.49	460.59
16 Reserves & Surplus excluding revaluation reserves				25,297.69
17 Analytical ratios:				
(i) Percentage of Shares held by Government of India	Nil	Nil	Nil	Nil
(ii) Capital Adequacy ratio - Basel III	16.9%	18.4%	17.1%	18.4%
(iii) Earning per share for the period / year (before and after extraordinary items)				
- Basic ₹	5.47	5.14	4.22	18.43
- Diluted ₹	5.39	5.06	4.13	18.06
(iv) NPA ratios -	Not Annualized	Not Annualized	Not Annualized	Annualized
(a) Gross NPA	2,824.46	2,626.80	1,364.38	2,626.80
(b) Net NPA	1,262.57	1,312.75	545.31	1,312.75
(c) % of Gross NPA	1.31%	1.28%	0.97%	1.28%
(d) % of Net NPA	0.59%	0.64%	0.39%	0.64%
(v) Return on assets (average) (annualized)	1.6%	1.6%	1.8%	1.6%

YES BANK

receives regulatory approvals to launch Mutual Fund business
July 2018

CARE

YES BANK upgraded to 'AAA' with stable outlook by CARE Ratings
July 2018

CNBC TV18

The prestigious CNBC Asia's India Talent Management Award to RANA KAPOOR
April 2018

FORBES GLOBAL 2000

Ranked #1,013 Forbes Global 2000
Ranked #155 Growth Champions
Forbes Global 2000 World's Largest Public Companies
June 2018

Notes:

- The results have been taken on record by the Board of Directors of the Bank at its meeting held in Mumbai today. The results have been subject to "Limited Review" by the Statutory Auditors of the Bank. There are no qualifications in the auditor's review report for the quarter ended June 30, 2018.
- The shareholders of the sub-division of each equity share having a face value of ₹ 10 into five equity shares having a face value of ₹ 2 each through postal ballot on September 8, 2017. The record date for the sub-division was September 22, 2017. All shares and per share information in the financial results are restated to reflect the effect of sub-division for each of the periods presented.
- During the quarter ended June 30, 2018, the Bank allotted 2,745,850 shares, pursuant to the exercise of stock options by certain employees.
- Other income includes fees and commission earned from guarantees/letters of credit, loans, financial advisory fees, selling of third party products, earnings from foreign exchange transactions and profit/loss from sale of securities.
- As at June 30, 2018, the total capital infused and outstanding is ₹ 5,000 Lakhs in Yes Securities (India) Limited, ₹ 7,450 Lakhs in YES Asset Management (India) Limited and ₹ 50 Lakhs in Yes Trustee Limited. All three are wholly owned subsidiary companies of the Bank.
- Return on assets is computed using a simple average of total assets at the beginning and at the end of the relevant period.
- The disclosures for NPA referred to in point 17(v) above correspond to Non Performing Advances.
- In view of the continuing rise in the yields on Government Securities, RBI vide its circular DBR.No.BP.BC.102/21.04.048/2017-18 dated April 02, 2018 and DBR.No.BP.BC.113/21.04.048/2017-18 dated June 15, 2018 has granted banks the option to spread provisioning for their net mark to market (MTM) losses on all investments held in AFS and HFT for the quarter ended March 31, 2018 and June 30, 2018. As per the RBI circular, the provisioning cost for the quarter may be spread equally over up to four quarters, commencing with the quarter ended March 31, 2018 and June 30, 2018 respectively. For the quarter ending June 30, 2018, the Bank has considered a provision of ₹ 9,267.23 Lakhs and will amortize ₹ 27,801.70 Lakhs over the subsequent quarters for the year ending March 31, 2019. The Bank had however not availed of the said option and recognized the entire net mark to market loss on investments in the quarter ended March 31, 2018.
- As the business of the Bank is concentrated in India, the segment disclosures made pertain to domestic segment.
- In accordance with RBI master circular DBR.No.BP.BC.1/21.06.201/2015-16 dated July 1, 2015 on 'Basel III Capital Regulations' read together with RBI circular DBR.No.BP.BC.02/21.06.201/2014-15 dated March 31, 2015 on 'Prudential Guidelines on Capital Adequacy and Liquidity Standards - Amendments' requires banks to make applicable Pillar III disclosures including leverage ratio and liquidity coverage ratio under Basel III Framework. The Pillar III disclosures have not been subjected to review by the statutory auditors. The Bank has made these disclosures which are available on its website at the following link: https://www.yesbank.in/pdf/basel_iii_disclosure_june_30_2018.pdf
- The figures of quarter ended March 31, 2018 are the balancing figures between audited figures in respect to the full financial year upto March 31, 2018 and the unaudited published year to date figures upto December 31, 2017, being the date of the end of the third quarter of the financial year which was subject to limited review.
- The Bank has followed the same significant accounting policies in the preparation of these financial results as those followed in the annual financial statement for the year ended March 31, 2018.
- Previous period figures have been regrouped /reclassified wherever necessary to conform to current period classification.

Place: Mumbai
Date: July 26, 2018

For YES BANK Limited
Rana Kapoor
Managing Director & CEO

YES BANK

1,105 Branches Pan India | 1,750+ ATMs | 20,000+ YES Bankers

YES BANK LIMITED: Registered Office: Nehru Centre, 9th Floor, Discovery of India Bldg, Dr. A.B. Road, Worli, Mumbai 400 018, India.
Website: www.yesbank.in, Tel: +91(22) 6669 9000, Fax: +91(22) 2490 0314, Email: communications@yesbank.in, CIN: L65190MH2003PLC143249

Biocon profit jumps 47% in June quarter

AGENCIES
Bengaluru/New Delhi, July 26

BIOCON REPORTED A 47% rise in the June quarter profit on Thursday, helped by higher income from its biologics and research services businesses.

Net profit rose to ₹120 crore for the quarter ended June 30, from ₹81.3 crore last year, India's largest biotechnology company, said in a statement. Revenue from operations rose 20.4% to ₹1,124 crore. Analysts on average were expecting a net profit of ₹117 crore, according to Thomson Reuters.

"We started the year with a robust Q1FY19 recording an overall revenue growth of 21% at ₹1,193 crore and a 47% rise in net profit at ₹120 crore, driven by a strong performance across our business segments," Biocon chairperson and MD Kiran Mazumdar-Shaw said.

Dr Reddy's posts eight-fold jump in net

FE BUREAU
Hyderabad, July 26

DR REDDY'S LABORATORIES has posted an eight-fold jump in its consolidated net profit, clocking ₹456.1 crore against ₹59.1 crore, aided by operational efficiencies, forex gains and launch of gSuboxone, the generic version of an opioid addiction drug in the US market during the first quarter.

Consolidated revenues stood at ₹3,720.7 crore against ₹3,315.9 crore in the same quarter last year. Earnings before interest, tax, depreciation and amortisation (Ebitda) for the quarter stood at ₹807.1 crore, an increase of 140% year-on-year (y-o-y).

"Our focus on operational efficiencies has helped in significantly improving our margin profile. Looking ahead, while we may continue to experience price erosion in the North America Generics

market, we will also continue to drive growth and cost efficiencies, at the same time, enhancing our quality management systems and building healthy portfolios across the markets we serve," company co-chairman and CEO, GV Prasad said.

The focus will continue on building complex generics, biosimilars and differentiated products pipeline, he added.

"Part of the gross margin improvement is attributed to gSuboxone, but there has been benefit from forex gains and operating efficiencies as well.



The forex gain has also contributed 400-500 basis points to the profit," Saumen Chakraborty, CFO and global head of HR, Dr Reddy's, said.

The company was selling

Consolidated revenues stood at ₹3,720.7 crore against ₹3,315.9 crore in the same quarter last year, while Ebitda stood at ₹807.1 crore, an increase of 140%

generic product in the US market prior to the grant of a temporary restraining order (TRO). To recall, the New Jersey District Court has granted a preliminary injunction against Dr Reddy's on the sale of a generic

version of Indivior's prescription medicine gSuboxone in the US market. The court has prevented Dr Reddy's from re-launching its generic product until the patent litigation by Indivior is concluded or until it prevails on an appeal of this injunction.

Revenues from emerging markets, which contribute 18% of generic sales business, declined 21% to ₹664.3 crore. However, revenues from Russia grew 9% to ₹380 crore on account of new launches and volume traction in some of the key molecules.

Colgate-Palmolive Q1 net profit at ₹190 cr

New Delhi, July 26

FMCG MAJOR Colgate-Palmolive India (CPIL) on Thursday reported net profit of ₹189.51 crore for the first quarter of 2018-19, led by strong volume growth.

The company had posted net profit of ₹136.38 crore in the April-June quarter last fiscal, 2017-18, CPIL said in a BSE filing.

Net sales during the quarter under review were at ₹1,033.55 crore. They were at ₹1,109.88 crore in the year-

ago period.

CPIL MD Issam Bachalrani said: "The company registered volume growth of 4% in the first quarter with strong performance in naturals portfolio."

According to the company, the sales for the quarter are net of GST, while the year-ago figures include excise duty which has now been subsumed after implementation of GST. Hence, the results are not comparable.

Its total expenses were also down 14.40% to ₹799.10 crore.

MARUTI SUZUKI
Way of Life!

MARUTI SUZUKI INDIA LIMITED

Registered Office: Plot No.1, Nelson Mandela Road, Vasant Kunj, New Delhi - 110070

CIN: L34103DL1981PLC011375; Website: www.marutisuzuki.com; E-mail: investor@maruti.co.in; Phone: +91-11-46781000; Fax: +91-11-46150275/76

INR in million, except per share data

Sl. No.	Particulars	Quarter ended			Year ended
		30th June, 2018	31st March, 2018	30th June, 2017	31st March, 2018
		Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations	224,594	211,656	197,774	819,944
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	28,824	26,344	22,987	110,034
3	Net Profit / (Loss) for the period (before Tax, after Exceptional and / or Extraordinary Items)	28,824	26,344	22,987	110,034
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	19,753	18,821	15,564	77,218
5	Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	19,606	17,710	16,281	80,530
6	Equity Share Capital	1,510	1,510	1,510	1,510
7	Earnings Per Share (of INR 5 each) (for continuing and discontinued operations)				
	(a) Basic	65.39	62.30	51.52	255.62
	(b) Diluted	65.39	62.30	51.52	255.62

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com and on Company's website at www.marutisuzuki.com.

For and on behalf of Board of Directors

New Delhi
26th July, 2018

(Kenichi Ayukawa)
Managing Director & CEO

A. K. CAPITAL SERVICES LTD.
BUILDING BONDS
Regd. Office: 403, 4th Floor, East Wing, Tulsiani Chambers, Free Press Journal Marg, 212, Nariman Point, Mumbai - 400021.
CIN: L74899MH1993PLC274881 | Website: www.akgroup.co.in
Tel: +91-22-67546500 | Fax: +91-22-66100594 | E-mail: compliance@akgroup.co.in

NOTICE OF RECORD AND BOOK CLOSURE DATE

In pursuance to the Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at their Meeting held on Saturday, May 26, 2018 had decided Friday, August 10, 2018 as the "Record Date" for the purpose of ascertaining the eligibility of the shareholders for the payment of final dividend if approved at the ensuing Annual General Meeting.

Further, pursuant to Section 91 of the Companies Act, 2013 and Rule 10 of the Companies (Management and Administration) Rules, 2014 read with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and the Share Transfer Books of the Company will remain closed from Saturday, August 11, 2018 to Saturday, August 18, 2018 (both days inclusive) in order to ascertain the entitlement of final dividend, if declared at the ensuing Annual General Meeting.

The said notice is also available on www.bseindia.com and www.akgroup.co.in.

For A. K. Capital Services Limited
Sd/-
A. K. Mittal
Managing Director
(DIN: 00698377)

Date: July 26, 2018
Place: Mumbai

SUN PHARMA
Regd. Office: SPARC, Tandajda, Vadodara - 390 012
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon-East, Mumbai - 400 063
CIN: L24230GJ1993PLC019050 | Website: www.sunpharma.com
Tel: 022-43244324/022-43241234

NOTICE

NOTICE is hereby given pursuant to Regulation 47(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that the Meeting of the Board of Directors of the Company will be held on Tuesday, August 14, 2018, inter alia, to consider and take on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2018.

This Notice is also available on the Company's website www.sunpharma.com and on the websites of BSE Limited and National Stock Exchange of India Limited i.e. www.bseindia.com and www.nseindia.com respectively.

By order of the Board of Directors
For Sun Pharmaceutical Industries Limited
Sd/-
Ashok I. Bhuta
Place: Mumbai
Date: July 26, 2018
Sr. GM - Secretarial & Compliance Officer

YES BANK

SUSTAINED FINANCIAL PERFORMANCE



* including profits & adjusted for prorated dividend & IFR

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2018

PARTICULARS (₹ in Crores)	FOR THE QUARTER ENDED 30.06.18 (Unaudited)	FOR THE QUARTER ENDED 31.03.18 (Audited Ref Note 11)	FOR THE QUARTER ENDED 30.06.17 (Unaudited)	FOR THE YEAR ENDED 31.03.18 (Audited)
1 Interest earned (a)+(b)+(c)+(d)	6,578.04	5,742.98	4,653.80	20,267.42
(a) Interest/discount on advances/bills	5,004.66	4,404.41	3,534.48	15,478.24
(b) Income on investments	1,350.86	1,179.44	902.72	4,102.53
(c) Interest on balances with Reserve Bank of India and other inter-bank funds	162.03	109.60	179.36	516.07
(d) Others	60.49	49.53	37.24	170.58
2 Other Income (Refer Note 4)	1,694.14	1,420.97	1,132.16	5,223.83
3 TOTAL INCOME (1+2)	8,272.18	7,163.95	5,785.96	25,491.25
4 Interest Expended	4,358.90	3,588.74	2,844.87	12,530.36
5 Operating Expenses (i)+(ii)	1,458.57	1,439.78	1,236.89	5,212.78
(i) Payments to and provisions for employees	590.62	546.67	546.11	2,188.92
(ii) Other operating expenses	867.95	893.11	690.78	3,023.86
6 Total Expenditure (4+5) (excluding provisions & contingencies)	5,817.47	5,028.52	4,081.76	17,743.14
7 Operating Profit (before Provisions and Contingencies)(3-6)	2,454.71	2,135.43	1,704.20	7,748.11
8 Provisions (other than Tax expense) and Contingencies (net)	625.65	399.64	285.78	1,553.80
9 Exceptional Items	-	-	-	-
10 Profit from ordinary activities before tax (7-8-9)	1,829.06	1,735.79	1,418.42	6,194.31
11 Tax Expense	568.70	556.35	452.90	1,969.75
12 Net profit from Ordinary Activities after tax (10-11)	1,260.36	1,179.44	965.52	4,224.56
13 Extraordinary Items (Net of tax)	-	-	-	-
14 NET PROFIT (12-13)	1,260.36	1,179.44	965.52	4,224.56
15 Paid-up equity Share Capital (Face value of ₹ 2 each)	461.14	460.59	457.49	460.59
16 Reserves & Surplus excluding revaluation reserves				25,297.69
17 Analytical ratios:				
(i) Percentage of Shares held by Government of India	Nil	Nil	Nil	Nil
(ii) Capital Adequacy ratio - Basel III	16.9%	18.4%	17.1%	18.4%
(iii) Earning per share for the period / year (before and after extraordinary items)				
- Basic ₹	5.47	5.14	4.22	18.43
- Diluted ₹	5.39	5.06	4.13	18.06
(iv) NPA ratios -	Not Annualized	Not Annualized	Not Annualized	Annualized
(a) Gross NPA	2,824.46	2,626.80	1,364.38	2,626.80
(b) Net NPA	1,262.57	1,312.75	545.31	1,312.75
(c) % of Gross NPA	1.31%	1.28%	0.97%	1.28%
(d) % of Net NPA	0.59%	0.64%	0.39%	0.64%
(v) Return on assets (average) (annualized)	1.6%	1.6%	1.8%	1.6%

YES BANK

receives regulatory approvals to launch Mutual Fund business July 2018

CARE

YES BANK upgraded to 'AAA' with stable outlook by CARE Ratings July 2018

CNBC TV18

The prestigious CNBC Asia's India Talent Management Award to RANA KAPOOR April 2018

FORBES GLOBAL 2000

Ranked #1,013 Forbes Global 2000
Ranked #155 Growth Champions
Forbes Global 2000 World's Largest Public Companies June 2018

Notes:

- The results have been taken on record by the Board of Directors of the Bank at its meeting held in Mumbai today. The results have been subject to "Limited Review" by the Statutory Auditors of the Bank. There are no qualifications in the auditor's review report for the quarter ended June 30, 2018.
- The shareholders of the sub-division of each equity share having a face value of ₹ 10 into five equity shares having a face value of ₹ 2 each through postal ballot on September 8, 2017. The record date for the sub-division was September 22, 2017. All shares and per share information in the financial results are restated to reflect the effect of sub-division for each of the periods presented.
- During the quarter ended June 30, 2018, the Bank allotted 2,745,850 shares, pursuant to the exercise of stock options by certain employees.
- Other income includes fees and commission earned from guarantees/letters of credit, loans, financial advisory fees, selling of third party products, earnings from foreign exchange transactions and profit/loss from sale of securities.
- As at June 30, 2018, the total capital infused and outstanding is ₹ 5,000 Lakhs in Yes Securities (India) Limited, ₹ 7,450 Lakhs in YES Asset Management (India) Limited and ₹ 50 Lakhs in Yes Trustee Limited. All three are wholly owned subsidiary companies of the Bank.
- Return on assets is computed using a simple average of total assets at the beginning and at the end of the relevant period.
- The disclosures for NPA referred to in point 17(v) above correspond to Non Performing Advances.
- In view of the continuing rise in the yields on Government Securities, RBI vide its circular DBR.No.BP.BC.102/21.04.048/2017-18 dated April 02, 2018 and DBR.No.BP.BC.113/21.04.048/2017-18 dated June 15, 2018 has granted banks the option to spread provisioning for their net mark to market (MTM) losses on all investments held in AFS and HFT for the quarter ended March 31, 2018 and June 30, 2018. As per the RBI circular, the provisioning cost for the quarter may be spread equally over up to four quarters, commencing with the quarter ended March 31, 2018 and June 30, 2018 respectively. For the quarter ending June 30, 2018, the Bank has considered a provision of ₹ 9,267.23 Lakhs and will amortize ₹ 27,801.70 Lakhs over the subsequent quarters for the year ending March 31, 2019. The Bank had however not availed of the said option and recognized the entire net mark to market loss on investments in the quarter ended March 31, 2018.
- As the business of the Bank is concentrated in India; the segment disclosures made pertain to domestic segment.
- In accordance with RBI master circular DBR.No.BP.BC.1/21.06.201/2015-16 dated July 1, 2015 on 'Basel III Capital Regulations' read together with RBI circular DBR.No.BP.BC.02/21.06.201/2014-15 dated March 31, 2015 on 'Prudential Guidelines on Capital Adequacy and Liquidity Standards - Amendments' requires banks to make applicable Pillar III disclosures including leverage ratio and liquidity coverage ratio under Basel III Framework. The Pillar III disclosures have not been subjected to review by the statutory auditors. The Bank has made these disclosures which are available on its website at the following link: https://www.yesbank.in/pdf/basel_iii_disclosure_june_30_2018.pdf
- The figures of quarter ended March 31, 2018 are the balancing figures between audited figures in respect to the full financial year upto March 31, 2018 and the unaudited published year to date figures upto December 31, 2017, being the date of the end of the third quarter of the financial year which was subject to limited review.
- The Bank has followed the same significant accounting policies in the preparation of these financial results as those followed in the annual financial statement for the year ended March 31, 2018.
- Previous period figures have been regrouped /reclassified wherever necessary to conform to current period classification.

Place: Mumbai
Date: July 26, 2018

For YES BANK Limited
Rana Kapoor
Managing Director & CEO

YES BANK

1,105 Branches Pan India | 1,750+ ATMs | 20,000+ YES Bankers

YES BANK LIMITED: Registered Office: Nehru Centre, 9th Floor, Discovery of India Bldg, Dr. A.B. Road, Worli, Mumbai 400 018, India. Website: www.yesbank.in, Tel: +91(22) 6669 9000, Fax: +91(22) 2490 0314, Email: communications@yesbank.in, CIN: L65190MH2003PLC143249

अभ्यास मैच में भारत का पलड़ा भारी

वेस्टइंडीज, 26 जुलाई (भासा)।

भारत ने तीन दिवसीय अभ्यास मैच के दूसरे दिन पहली पारी में 395 रन बनाते के बाद वेस्टइंडीज को घाबराया था। भारत ने 395 रन बनाते के बाद वेस्टइंडीज को घाबराया था। भारत ने 395 रन बनाते के बाद वेस्टइंडीज को घाबराया था।

395 रन के जवाब में एसेम्स ने 186 रन तक पांच विकेट गंवाए

वेस्टइंडीज की पारी 34 रन बनाकर नाबाद रहे। एसेम्स की ओर से वाल्डर ने 113 रन बनाकर बाएं हाथी गेंदबाज के रूप में उभरे। वेस्टइंडीज की पारी 34 रन बनाकर नाबाद रहे। एसेम्स की ओर से वाल्डर ने 113 रन बनाकर बाएं हाथी गेंदबाज के रूप में उभरे।

आइडब्लूएफ ने संजीता चानू डोप मामले में प्रशासनिक गलती मानी

दिल्ली, 26 जुलाई (भासा)।

भारतीय ओलंपिक समिति (आइडब्लूएफ) ने संजीता चानू के डोप मामले में प्रशासनिक गलती मानी। भारतीय ओलंपिक समिति (आइडब्लूएफ) ने संजीता चानू के डोप मामले में प्रशासनिक गलती मानी।

वेस्टइंडीज की पारी 34 रन बनाकर नाबाद रहे। एसेम्स की ओर से वाल्डर ने 113 रन बनाकर बाएं हाथी गेंदबाज के रूप में उभरे।

नाराज आइओए ने खिलाड़ियों से हुए नुकसान की भरपाई के लिए कहा

दिल्ली, 26 जुलाई (भासा)।

भारतीय ओलंपिक समिति (आइओए) ने नाराज आइओए को नुकसान की भरपाई के लिए कहा। भारतीय ओलंपिक समिति (आइओए) ने नाराज आइओए को नुकसान की भरपाई के लिए कहा।

वेस्टइंडीज की पारी 34 रन बनाकर नाबाद रहे। एसेम्स की ओर से वाल्डर ने 113 रन बनाकर बाएं हाथी गेंदबाज के रूप में उभरे।

इंग्लैंड की टैस्ट टीम में आदिल राशिद की वापसी, पोर्टर भी शामिल

पार्थीव ने जल रहे लोग सिमरन आदिल राशिद ने भारत के खिलाफ पहले टेस्ट के लिए मुंबई को इंग्लैंड की 13 सदस्यीय टीम में शामिल की। पार्थीव ने जल रहे लोग सिमरन आदिल राशिद ने भारत के खिलाफ पहले टेस्ट के लिए मुंबई को इंग्लैंड की 13 सदस्यीय टीम में शामिल की।



HIGHEST-EVER QUARTERLY SALES OF 2,106,829 UNITS IN Q1 FY'19 | REPORTS REVENUE OF ₹810 CRORE; PAT OF ₹909 CRORE

Statement of Un-Audited Financial Results for the quarter ended June 30, 2018.

S.No.	Particulars	Standalone		
		Quarter ended June 30, 2018 Un-Audited	Quarter ended June 30, 2017 Audited	Year ended March 31, 2018 Audited
1	Total Income	8,925.55	8,763.53	33,397.64
2	Net Profit for the period before Tax (before Exceptional items)	1,342.74	1,293.08	5,244.16
3	Net Profit for the period before tax (after Exceptional items)	1,342.74	1,293.08	5,244.16
4	Net Profit for the period after tax (after Exceptional items)	909.17	914.04	3,697.96
5	Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	905.99	910.82	3,692.65
6	Equity Share Capital (face value ₹2/- per share)	39.94	39.94	39.94
7	Earnings per share on net profit after tax - face value ₹2/- each (in Rupees)			
	a) Basic	45.52	45.77	185.14
	b) Diluted	45.52	45.77	185.13

No exceptional item during the period. The above is an extract of the unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosures Requirements) Regulations, 2015. The full text of the Quarterly Financial Results is available on the Company's website: www.heronmotorcycle.com and also on stock exchange websites: www.bseindia.com and www.nseindia.com. Based on the auditing firm's report dated 25.07.2018, the Company's business activities fall within a single operating segment, namely automobile segment. Accordingly, the disclosure requirements of INDAS 100 are not applicable. The above results for the quarter ended June 30, 2018 have been reviewed and recommended by the Audit Committee, meeting held on July 24, 2018 and approved by the Board of Directors in their meeting held on July 25, 2018. For and on behalf of the board: PANKAJ MUKHARJIA, Chairman, Managing Director & CEO, DIN: 06501923

विश्व कप में भारतीय महिला हॉकी टीम आयरलैंड से हारी

लंदन, 26 जुलाई (भासा)।

भारतीय महिला हॉकी टीम मुंबई को घाबराया था। भारतीय महिला हॉकी टीम मुंबई को घाबराया था। भारतीय महिला हॉकी टीम मुंबई को घाबराया था।

भारतीय महिला हॉकी टीम मुंबई को घाबराया था। भारतीय महिला हॉकी टीम मुंबई को घाबराया था। भारतीय महिला हॉकी टीम मुंबई को घाबराया था।

MARUTI SUZUKI INDIA LIMITED

Registered Office: Plot No.1, Nelson Mandela Road, Vasant Kunj, New Delhi - 110070

CIN: L34103DL1981PLC011375; Website: www.marutisuzuki.com; E-mail: investor@maruti.co.in; Phone: +91-11-46781000; Fax: +91-11-45150275/76

Sl. No.	Particulars	Quarters ended		Year ended	
		30th June, 2016 Unaudited	31st March, 2018 Unaudited	30th June, 2017 Unaudited	31st March, 2018 Audited
1	Total Income from Operations	292,584	211,659	107,774	219,940
2	Net Profit (Loss) for the period before Tax (Exceptional item) / or Extraordinary Items	28,524	20,344	27,207	110,034
3	Net Profit (Loss) for the period before Tax (after Exceptional item) / or Extraordinary Items	28,524	20,344	27,207	110,034
4	Net Profit (Loss) for the period after Tax (after Exceptional item) / or Extraordinary Items	19,752	19,021	15,565	77,218
5	Total Comprehensive Income for the period (Comprising Profit (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	19,006	17,710	16,081	80,530
6	Equity Share Capital	1,510	1,610	1,610	1,510
7	Earnings Per Share (EPS) (for continuing and discontinued operations)				
	(a) Basic	65.39	69.30	51.39	256.62
	(b) Diluted	65.39	69.30	51.52	258.02

The above is an extract of the unaudited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosures Requirements) Regulations, 2015. The full text of the quarterly financial results is available on the website of the Company at www.marutisuzuki.com and on the stock exchange websites: www.bseindia.com and www.nseindia.com.

For and on behalf of Board of Directors: (GenetiK Ayukawa) Managing Director & CEO

New Delhi, 26th July 2018